Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity
11:36am, Monday, 11'th Aug 2025
Regeneron's Q2 showed strong earnings and cash flow, driven by DUPIXENT's growth and operational discipline, despite EYLEA's ongoing revenue decline. EYLEA faces intense competition and margin pressur
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings
02:05pm, Monday, 04'th Aug 2025
On Friday, Regeneron Pharmaceuticals Inc. REGN reported upbeat second-quarter earnings.
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts
06:00am, Sunday, 03'rd Aug 2025
The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other produ
Regeneron (REGN) Q2 EPS Jumps 53%
06:09am, Saturday, 02'nd Aug 2025
Regeneron (REGN) Q2 EPS Jumps 53%
Regeneron: Rapidly Decreasing Importance Of Eylea
04:05pm, Friday, 01'st Aug 2025
Regeneron Pharmaceuticals delivered strong Q2 results, driven by Dupixent and Libtayo growth that were enough to offset the decline of the Eylea franchise. The existing product portfolio and upcoming
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
01:46pm, Friday, 01'st Aug 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO George D.
Nonfarm Payrolls Come in SIgnificantly Below Expectations
12:11pm, Friday, 01'st Aug 2025
Nonfarm Payrolls Come in SIgnificantly Below Expectations.
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
12:11pm, Friday, 01'st Aug 2025
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
10:30am, Friday, 01'st Aug 2025
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street
US FDA declines to approve Regeneron's blood cancer therapy for second time
10:10am, Friday, 01'st Aug 2025
Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, this time in relation to observations from the regulator's inspection at a t
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
08:46am, Friday, 01'st Aug 2025
Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per share. This compares to earnings of $11.56 per share a year ago.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
Regeneron beats second-quarter results estimates on Dupixent sales boost
08:22am, Friday, 01'st Aug 2025
Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up nearl
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
